Not every asset needs the same future.
Phase 2 produced a heterogeneous portfolio. Phase 3 can advance selected assets or clusters independently through validation, licensing, pilots, research, investment or integration. HUAI and Zoyan are optional convergence destinations—not mandatory endpoints.
The right Phase 3 question is not “how do we commercialize everything?” It is “which object deserves which next step?”
One portfolio. Different counterparties.
These are representative paths, not an exhaustive taxonomy of the 330+ mapped Phase 2 assets and sub-assets.
GPU Sentinel
Possible Phase 3: independent benchmark, security review, enterprise pilot, licensing/OEM, infrastructure partnership.
Inspect GPU → Tokenizer / RepresentationTokenizer
Possible Phase 3: model integration, technical diligence, licensing, performance evaluation, research collaboration.
Inspect Tokenizer → ArchitectureLLM Anatomy
Possible Phase 3: technical framework review, enterprise/lab evaluation, architecture consulting or strategic diligence.
Inspect LLM Anatomy → FrameworkLLM Complement Framework
Possible Phase 3: architecture review, selected implementation, enterprise integration or research collaboration.
Inspect Framework → SecurityZOE / ISBP
Possible Phase 3: specialist security review, threat reproduction, confidential mitigation diligence, controlled pilot.
Inspect Security → ResearchBioCode / HDTP
Possible Phase 3: research review, protocol testing, institutional collaboration, IP strategy or selected implementation.
Inspect Research →Asset, cluster or program.
Phase 3 scope should match the actual counterparty and the evidence object.
One technical or research object with its own diligence and terms.
A related family such as LLM systems, security, optimization or research.
A strategic operating path such as Mazzaneh, HUAI, Zoyan or OPU advancement.